No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Nanjing Vazyme Biotech Co., Ltd., a prominent biotechnology firm, specializes in the comprehensive investigation, development, and manufacturing of essential biological components. These core offerings include enzymes, antigens, antibodies, and unique polymer organic compounds. The company's extensive product portfolio encompasses a broad spectrum of scientific research reagents. This range features solutions for advanced techniques such as PCR cloning and point mutation, nucleic acid extraction, reverse transcription, quantitative PCR (qPCR), cell and protein analysis, gene editing applications, and user-friendly instant granule formulations. Furthermore, Vazyme provides sophisticated reagents crucial for high-throughput sequencing library construction, including those for DNA and RNA library preparation, single-cell epigenetics, magnetic bead-based methodologies, quantitative assays, and the effective storage and extraction of cell-free DNA. Complementing these, the company also delivers a variety of biomedical reagents and related services. Vazyme's diverse clientele spans scientific research institutions, specialized high-throughput sequencing service providers, manufacturers of molecular diagnostic reagents, pharmaceutical enterprises, contract research organizations (CROs), hospitals, and other healthcare facilities. Established in 2012, the company maintains its headquarters in Nanjing, China.
www.vazymeglobal.comNo one on the platform currently holds 688105.SS.
No tracked institution reports a position in 688105.SS as of their last filing.
No one on the platform has traded 688105.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -0.0% | -2.5% | ||||
| Profit Margin % | -1.2% | 9.0% | ||||
| Free Cash Flow Margin % | 13.5% | 2.7% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.6B | +10.2% | $0.15 | $0.15–$0.16 | — | 2 |
| 2027 | $1.9B | +16.4% | $0.27 | $0.26–$0.28 | — | 2 |
| 2028 | $2.2B | +16.7% | $0.42 | $0.41–$0.43 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 688105.SSNanjing Vazyme Biotech Co., Ltd. | $21.13 | +4.71% | $10.9B | — |
| 000990.SZChengzhi Shareholding Co., Ltd. | $6.37 | -1.55% | $10.8B | — |
| 002030.SZDaan Gene Co., Ltd. | $5.27 | +0.96% | $7.4B | — |
| 002275.SZGuilin Sanjin Pharmaceutical Co., Ltd. | $12.11 | -0.08% | $7.1B | — |
| 300705.SZHunan Jiudian Pharmaceutical Co., Ltd. | $10.54 | +0.96% | $5.3B | — |
| 300841.SZChengdu Kanghua Biological Products Co., Ltd. | $50.37 | +1.65% | $6.5B | — |
| 603229.SSZhejiang Ausun Pharmaceutical Co., Ltd. | $7.59 | +0.53% | $6.3B | — |
Source: Financial Modeling Prep · peers by sector/industry